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ORIGINAL ARTICLELocal Recurrence and Breast Oncological Surgery in Young
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Sue Gerty, MSc, Ellen. R. Copson, BSc, MBBS, MRCP, PhD,y Lorraine Durcan, BSc,
and Diana M. Eccles, MB ChB, MD, FRCPObjective: To assess clinical and surgical factors affecting local recurrence
and survival in young breast cancer patients in the Prospective study of
Outcomes in Sporadic versus Hereditary breast cancer (POSH).
Background: Emerging data suggest young age is a predictor of increased
local recurrence.
Methods: POSH is a prospective cohort of 3024 women of 18 to 40 years
with breast cancer. Cohort characteristics were grouped by mastectomy or
BCS. Endpoints were local-recurrence interval (LRI), distant disease-free
interval (DDFI), and overall survival (OS); described using cumulative-hazard
and Kaplan-Meier plots and multivariable analyses by Flexible Parametric
and Cox regression models.
Results: Mastectomy was performed in 1464 patients and breast-conserving
surgery (BCS) in 1395. Patients undergoing mastectomy had larger tumors
and higher proportions of positive family history, estrogen receptorþ, pro-
gesterone receptorþ, and/or human epidermal growth factor receptor 2þ
tumors. Local events accounted for 15% of recurrences. LRI by surgical type
varied over timewith LRI similar at 18 months (1.0% vs 1.0%, P¼ 0.348) but
higher for BCS at 5 and 10 years (5.3% vs 2.6%, P < 0.001; and 11.7% vs
4.9%, P < 0.001, respectively). Similar results were found in the adjusted
model. Conversely, distant-metastases and deaths were lower for BCS but not
after adjusting for prognostic factors. After mastectomy chest-wall radio-
therapy was associated with improved LRI (hazard ratio, HR ¼ 0.46, P ¼
0.015). Positive surgical margins, and development of local recurrencepredicted for reduced DDFI (HR ¼ 0.50, P < 0.001; and HR ¼ 0.29,
P ¼ 0.001, respectively).
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B reast cancer is the most common cancer in young adult women(age,40 years) in the UK, with over 2000 new cases annually.1
Young women have been found to develop more aggressive tumors
coupled with lower survival and higher local-recurrence rates (LRR)
than older women,2–9 and this may be a particular issue in the
developing world where a greater proportion of breast cancer appears
in women of young age.7,8 The choice between mastectomy and
breast-conserving surgery (BCS) in young women is not often a
straightforward decision for clinician and/or patient.10 BCS is
associated with better quality of life but higher LRR,4,11 although
a meta-analysis of mostly registry and database studies in patients
<40 years suggests equivalent disease-free and overall survival,12
whereas very young age (<35 years) has been considered a relative
contraindication to BCS.13 Although randomized controlled trials
(RCTs) suggest equivalent survival for mastectomy and BCS, very
few young patients were included in these analyses.6,14 Indeed,
young women are not routinely analyzed or reported separately in
individual RCTs of BCS versus mastectomy, and any that do have
very few women 40 years presented.12
Emerging evidence suggests a possible survival advantage for
mastectomy in BRCA gene-mutation carriers.15 Young patients are
more likely to be BRCA-mutation positive5 and retrospective cohort
studies suggest that LRR are higher for BCS compared with mas-
tectomy.6,10,11,16 Although family history does not affect clinical
outcome in young patients, it appears to affect surgical type selection,
and it is unknown if family history of breast cancer will influence
local recurrence.17
The effect of radiotherapy plays a key role in the treatment of
younger breast cancer patients. The Early Breast Cancer Trialists’
Collaborative Group (EBCTCG) found that women<40 years under-
going BCS had the highest incidence of recurrence and the largest
benefit from radiotherapy; with the 10-year recurrence rate (local or
distant) significantly lower compared with those without radiotherapy
(36.1% vs 60.7%, respectively, P ¼ 0.00009).18 Similar results were
seen in an RCT investigating the benefit of radiotherapy boost after
BCS, where the largest absolute benefit was seen in patients40 years
19with a significant relative-risk reduction for boost (P ¼ 0.003).
Likewise, an RCTof premenopausal women undergoing mastectomy
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significantly improved outcomes, even after controlling for clinical
and pathological factors,20 and aCanadian population registry study of
588 women <35 years found that LRR were reduced for postmastec-
tomy radiation.21
These differences observed in the effect of radiotherapy, and
the trend towards young patients having bilateral mastectomy as part
of their initial cancer treatment, demonstrate that an important
question remains about surgical type and outcomes in this age group.
Moreover, local recurrence is very important in young breast cancer
patients as there are a fewer competing risks and, other than their
breast cancer, their life expectation is longer. There are no large
prospective cohort studies reporting local recurrence in this age
group, and a dedicated RCT comparing mastectomy versus BCS
in young women is unlikely. A large prospective cohort study may
offer the best level of evidence, minimizing inclusion bias, to guide
management, and enable a comparison of local recurrence with
disease-free survival. The Prospective study of Outcomes in Sporadic
versus Hereditary breast cancer (POSH) is an observational cohort of
3000 young women with breast cancer, and is representative of the
UK breast cancer population.22 We have not previously reported
local-recurrence outcomes, and the aim of this analysis was therefore
to report breast ipsilateral LRR in the POSH study to determine
whether acceptable rates are found in a large cohort of young
patients, and what factors, including surgical type, affect these
outcomes in this age group.
METHODS
Study Population
POSH (MREC: 00/06/69) is a multicenter prospective obser-
vational cohort study of 3000 young women diagnosed with breast
cancer in the UK between 2000 and 2008 (http://www.southampto-
n.ac.uk/medicine/research/posh.page). All patients received treat-
ment according to local protocols. The detailed study protocol
was published in 2007,22 and the cohort previously described.23
For this analysis, type of surgery was defined as the final
oncological surgery to the breast for example, if a patient had BCS
followed by mastectomy 3 months; this was classed as a mastec-
tomy. A mastectomy performed >3 months after primary treatment
in the absence of local disease-recurrence was considered risk
reducing rather than oncological. Analyses of risk-reducing surgery
will be the subject of future work. Margin status was the final surgical
margin after oncological operation(s), and a positive margin was
defined according to American Society for Clinical Oncology
(ASCO) guidance as tumor at the margin (ie, tumor on ink).24 This
article presents analyses conducted on follow-up data from the POSH
cohort received until June 26, 2015.
Statistical Analysis
All analyses were conducted according to a prespecified plan
in line with published guidance.25 Patients with metastatic disease at
presentation were excluded. Summary statistics were used to
describe the cohort and key characteristics were compared by
surgical type using Pearson x2 tests or Mann-Whitney U tests. All
reported P-values were 2-sided.
Study endpointswere inbreast ipsilateral local-recurrence inter-
val (LRI), distant disease-free interval (DDFI), and overall survival
(OS). LRI was defined as time from date of diagnosis to date of local
recurrence (either an ipsilateral recurrence or ipsilateral new primary,
whichever event occurred first after BCSor chest-wall recurrence after
mastectomy).The local-recurrence eventwas counted as an event if the
date of the nonevent (death from breast cancer, distant metastases,
ipsilateral local axillary recurrence, ipsilateral regional nodes
2 | www.annalsofsurgery.com
Copyright © 2016 Wolters Kluwer Health, Inc. Unrecurrence, and/or contralateral recurrence, if/where applicable) was
>3months after the date of the local-recurrence event. If the date of the
nonevent was 3 months after the local recurrence event then the
patientwas censored at the date of nonevent.Deaths fromother cancers
after local recurrence did not affect the event.DFFIwas defined as time
from breast cancer diagnosis to distant metastases or death from breast
cancer; deaths fromother causeswere censored at the time of death.OS
was defined as time from breast cancer diagnosis to death from
any cause.
Nelson-Aalen cumulative-hazard plots were used to describe
LRI and Kaplan-Meier plots were used to describe DDFI and OS.
Univariable analyses (UVA) and multivariable analyses (MVA) were
carried out using Cox proportional-hazards models, or Flexible
Parametric Survival Models (FPSMs) for models which involved
time-varying hazards.26 Covariates included in the MVA models
included age at diagnosis (fitted as a continuous variable), tumor size,
focality, nodal (N) stage, histological grade, ER and HER2 tumor
status, adjuvant radiotherapy, adjuvant hormone therapy, and surgical
margins, regardless of significance. Patients treated with neoadjuvant
chemotherapy were included in UVA but excluded from all MVA
because of difficulties in classifying pathological Tand N staging for
these patients. For each FPSMs, we explored varying degrees of
freedom for the baseline-hazard rate and time-dependent effect to
obtain the best model fit.
All analyses were performed using STATA v13.1 (StataCorp,
College Station, TX, USA) on records with complete data (levels of
missing data were reported).
RESULTS
Patient Characteristics and Definitive Surgery
Information
The POSH study recruited 3095 patients across the United
Kingdom, and of 2882 included in this analysis (Fig. 1), 1464
(50.8%) underwent mastectomy and 1395 (48.4%) BCS. All patients
included underwent surgery to the axilla (axillary dissection, sentinel
node biopsy, or sample  axillary dissection). Twenty-three (0.8%)
patients underwent lymph node surgery only, with no surgery to the
breast. Table 1 shows baseline demographics by surgical type.
Median age at diagnosis was 36 years for mastectomy and BCS.
Family history of breast cancer was reported significantly more for
mastectomy compared with BCS (52.1% vs 48.1%, P ¼ 0.037), and
surveillance-detected tumors were more frequent for mastectomy
than BCS (1.5% vs 0.6%). However, no significant differences were
observed between surgical type for BMI and ethnicity.
Tumor Pathology
Significant differences in grade and focality were found
between mastectomy and BCS (P ¼ 0.005 and P < 0.001, respect-
ively). Patients undergoing mastectomy had larger tumors were more
likely to be human epidermal growth factor receptor 2þ (HER2þ)
and with a higher proportion of Extensive Intraductal Component
positive (EICþ) compared with BCS (P < 0.001 in all cases).
Patients undergoing mastectomy had a significantly higher
proportion of ERþ and/or PRþ tumors than BCS (estrogen receptor,
ER: 69.3% vs 62.8%, P < 0.001; progesterone receptor, PR: 59.3%
vs 53.9%, P ¼ 0.009, respectively).
Treatment and Surgery Information
Patients undergoing mastectomy had a higher frequency of
negative margins compared with BCS (P < 0.001). Specifically, the
proportion of margins >5mm was shown to be higher (42.7% vs
24.0%, respectively), whereas the proportion of margins 1 to 5mm
was lower for BCS (39.6% vs 55.0%, respectively).
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FIGURE 1. Flow chart for POSH study;
Annals of Surgery  Volume XX, Number X, Month 2016 Local Recurrence in Young Women With Breast CancerAlthough the median number of operations was one for
mastectomy and BCS, the distribution was significantly different
(P < 0.001), with a higher proportion of patients undergoing
mastectomy having more than one surgery (28.5% vs 20.8%,
P < 0.001). Only 11.1% of BCS patients underwent neoadjuvant
chemotherapy compared with 18.8% for mastectomy. Adjuvant
radiotherapy was given to 68.7% of patients undergoing a mastec-
tomy. In 56 patients undergoing BCS, we were unable to confirm
adjuvant breast radiotherapy. We cannot exclude that these patients
had radiotherapy to the breast at a different center and that the
information was not recorded, nor can we confirm that these patients
did not receive adjuvant breast radiotherapy. However, these patients
were analyzed as not having radiotherapy. Nine-hundred (61.5%)
patients undergoing mastectomy had chest-wall radiotherapy (CWR-
XRT) whereas 977 (70.0%) patients undergoing BCS had a radio-
therapy boost. In patients undergoing BCS, no clear association was
seen between margin status (>0/negative vs 0/positive) and provision
of a radiotherapy boost (data not shown).
Missing data were similar across surgical types and low for
most demographic information. Exceptions were PR, HER2, and
surgical margin information, with up to 19.7%, 13.3%, and 24.5%
missing, respectively.
Follow Up and Survival
Median follow up was 7.3 years for mastectomy, BCS, and
overall. There were 139 local-recurrence events compared with 752
DDFI events overall, demonstrating that the majority of events
experienced were because of distant metastases or death from breast
cancer (Fig. 1). Ninety-five local-recurrence events were experienced
for patients undergoing BCS (6.8% of these patients), compared with
just 40 (2.7%) for mastectomy. Two-hundred and sixty DDFI events
were experienced for BCS (18.6%), and 485 (33.1%) for mastec-
tomy. Similar numbers were found for OS, with 232 (16.6%) and 431
(29.4%) for BCS and mastectomy, respectively. Figure 2A shows the
Nelson-Aalen cumulative-hazard rates for LRI by surgical type.
local-recurrence analyses.There was no significant difference in the estimated 18-month
LRR between mastectomy and BCS (hazard ratio, HR: 1.43; 95%
 2016 Wolters Kluwer Health, Inc. All rights reserved.
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undergoing BCS had a significantly higher LRR at 5 years (2.63% vs
5.33%; HR, 3.39; 95% CI, 2.03–5.66; P < 0.001) and at 10 years
(4.93% vs 11.68%; HR, 5.27; 95% CI, 2.43–11.43; P < 0.001). The
change in HR over time is illustrated in Fig. 2B, with the HR crossing
one at 12 months. Similar results were found when excluding patients
with a maximum overall (invasiveþ in situ) tumor diameter>30mm
(thus excluding patients with larger tumors who were likely to be
treated with a mastectomy) (data not shown). MVA showed that
patients undergoing BCS also had a significantly higher chance of a
local recurrence at both 5 and 10 years, with only adjuvant radio-
therapy significantly affecting the MVA (Table 2). When looking at
LRI for mastectomy by CWR-XRT (Supplementary Figure 1A,
http://links.lww.com/SLA/B64), patients without CWR-XRT had a
significantly higher LRR compared with those with CWR-XRT (HR,
0.46; 95% CI, 0.24–0.86; P¼ 0.015). However, when assessing LRI
for BCS patients by radiotherapy boost, no significant differences
were found between patients with/without a boost (HR, 0.90; 95%
CI, 0.58–1.38; P ¼ 0.614) (Supplementary Figure 1B, http://link-
s.lww.com/SLA/B64). There was also no difference for BCS for
those with surgical margins of 0mm versus >0mm in terms of LRI
(HR, 0.86; 95% CI, 0.41–1.78; P ¼ 0.680) (Supplementary Figure
1C, http://links.lww.com/SLA/B64).
DDFI by surgical type showed that mastectomy patients had a
significantly worse DDFI than BCS (HR, 0.51; 95% CI, 0.44–0.60;
P < 0.001) (Fig. 3). However, in the MVA the difference was no
longer significant (HR, 0.82; 95% CI 0.64–1.05; P ¼ 0.115)
(Supplementary Table 1, http://links.lww.com/SLA/B64). Factors
affecting the MVA were maximum invasive tumor size, N stage,
grade, and ER status. DDFI by patients experiencing versus not
experiencing a local-recurrence event identified that DDFI was
similar at 5 years but the hazards separated at 10 years (HR, 0.80;
95% CI 0.54–1.18; P ¼ 0.263 and HR, 0.29; 95% CI 0.14–0.62;
P ¼ 0.001, respectively) (Supplementary Figure 2A, http://links.
lww.com/SLA/B64). When assessing DDFI by BCS patients with
surgical margins of 0mm versus>0mm, those with margins>0mm
had a significantly better DDFI compared with those with 0mm
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TABLE 1. Baseline Demographic Information for All Patients by Surgery Type
Characteristic
Mastectomy Breast Conserving Surgery Total
Py(n ¼ 1464) (n ¼ 1395) (n ¼ 2882)
Age at diagnosis, y 0.868
Median 36 36 36
Range 18 to 40 19 to 40 18 to 40
IQR 33 to 38 34 to 38 33 to 38
Missing 0 0 0
Body mass index 0.154
Median 24.5 24.8 24.6
Range 16.5 to 59.5, 16.8 to 55.9, 16.5 to 59.5,
IQR 22.0 to 28.1 22.1 to 28.4 22.1 to 28.4
Missing 44 (3.0%) 64 (4.6%) 108 (3.7%)
Race/ethnicity 0.436
White 1324 (91.9%) 1284 (93.2%) 2625 (92.4%)
Black 63 (4.4%) 44 (3.2%) 112 (3.9%)
Asian 43 (3.0%) 41 (3.0%) 84 (3.0%)
Other 10 (0.7%) 9 (0.7%) 20 (0.7%)
Missing 24 (1.6%) 17 (1.2%) 41 (1.4%)
Family history 0.037
No 672 (47.9%) 690 (51.9%) 1378 (50.0%)
Yes 731 (52.1%) 640 (48.1%) 1376 (50.0%)
Missing 61 (4.2%) 65 (4.7%) 128 (4.4%)
Presentation <0.001
Symptomatic 1424 (97.7%) 1380 (99.4%) 2826 (98.5%)
Screen detected 22 (1.5%) 8 (0.6%) 30 (1.0%)
Other 12 (0.8%) 0 12 (0.4%)
Missing 6 (0.4%) 7 (0.5%) 14 (0.5%)
Histological grade 0.005
Grade 1 68 (4.8%) 93 (6.8%) 161 (5.7%)
Grade 2 515 (36.2%) 429 (31.3%) 948 (33.7%)
Grade 3 840 (59.0%) 848 (61.9%) 1703 (60.6%)
Missing 41 (2.8%) 25 (1.8%) 70 (2.4%)
Histological type <0.001
Ductal 1246 (86.3%) 1230 (89.1%) 2494 (87.7%)
Lobular 85 (5.9%) 44 (3.2%) 131 (4.6%)
Ductal and lobular 50 (3.5%) 24 (1.7%) 74 (2.6%)
Other 83 (5.7%) 97 (7.0%) 183 (6.4%)
Missing 20 (1.4%) 15 (1.1%) 37 (1.3%)
Surgical margin <0.001
0 98 (8.9%) 113 (10.0%) 211 (9.4%)
0 to <1 97 (8.8%) 126 (11.1%) 223 (10.0%)
1 to 5 438 (39.6%) 624 (55.0%) 1062 (47.4%)
>5 472 (42.7%) 272 (24.0%) 745 (33.2%)
Missing 359 (24.5%) 260 (18.6%) 641 (22.2%)
EICz <0.001
Negative 1010 (72.8%) 1178 (86.8%) 2189 (79.7%)
Positive 378 (27.2%) 179 (13.2%) 557 (20.3%)
Missing 76 (5.2%) 38 (2.7%) 136 (4.7%)
Lymphovascular invasion <0.001
Absent 614 (45.1%) 784 (59.9%) 1402 (52.4%)
Present 747 (54.9%) 524 (40.1%) 1276 (47.6%)
Missing 103 (7.0%) 87 (6.2%) 204 (7.1%)
Number of positive nodes <0.001
0 549 (37.6%) 837 (60.5%) 1389 (48.7%)
1–3 532 (36.5%) 404 (29.2%) 940 (33.0%)
4–9 246 (16.9%) 99 (7.2%) 346 (12.1%)
10þ 132 (9.0%) 43 (3.1%) 175 (6.1%)
Missing 5 (0.3%) 12 (0.9%) 32 (1.1%)
ER status <0.001
Negative 449 (30.7%) 516 (37.2%) 975 (34.0%)
Positive 1013 (69.3%) 870 (62.8%) 1896 (66.0%)
Missing 2 (0.1%) 9 (0.6%) 11 (0.4%)
PR status 0.009
Negative 478 (40.7%) 519 (46.1%) 1008 (43.5%)
Positive 697 (59.3%) 607 (53.9%) 1309 (56.5%)
Missing 289 (19.7%) 269 (19.3%) 565 (19.6%)
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Mastectomy Breast Conserving Surgery Total
Py(n ¼ 1464) (n ¼ 1395) (n ¼ 2882)
HER2 status <0.001
Negative 906 (69.6%) 918 (75.9%) 1839 (72.7%)
Positive 395 (30.4%) 292 (24.1%) 691 (27.3%)
Missing 163 (11.1%) 185 (13.3%) 352 (12.2%)
Focality <0.001
Localised 707 (53.5%) 1136 (87.5%) 1845 (70.3%)
Multifocal 615 (46.5%) 163 (12.5%) 779 (29.7%)
Missing 142 (9.7%) 96 (6.9%) 258 (9.0%)
Maximum invasive tumor size (mm) <0.001
Median 28.5 19.0 22.0
Range 0.0 to 199.0, 0.0 to 90.0, 0.0 to 199.0,
IQR 19.0 to 43.0 14.0 to 25.0 15.0 to 33.0
Missing 93 (6.4%) 45 (3.2%) 160 (5.6%)
Maximum overall (invasive þ in situ) tumor size, mm <0.001
Median 37.0 20.5 27.0
Range 0.0 to 199.0, 0.0 to 115.0, 0.0 to 199.0,
IQR 25.0 to 55.0 15.0 to 27.0 18.0 to 40.0
Missing 68 (4.6%) 38 (2.7%) 128 (4.4%)
Number of operations, categorical <0.001
1 1047 (71.5%) 1105 (79.2%) 2174 (75.4%)
2 361 (24.7%) 279 (20.0%) 641 (22.2%)
3 53 (3.6%) 11 (0.8%) 64 (2.2%)
4 2 (0.1%) 0 2 (0.1%)
5 1 (0.1%) 0 1 (0.0%)
Missing 0 0 0
Chemotherapy treatment period <0.001
Adjuvant 1088 (74.3%) 1055 (75.6%) 2149 (74.6%)
Neoadjuvant 275 (18.8%) 155 (11.1%) 447 (15.5%)
Palliative 1 (0.1%) 0 1 (0.0%)
Not applicable 100 (6.8%) 185 (13.3%) 285 (9.9%)
Missing 0 0 0
Adjuvant trastazumab N/A
No/missing 1255 (85.7%) 1246 (89.3%) 2523 (87.5%)
Yes 209 (14.3%) 149 (10.7%) 359 (12.5%)
Missing 0 0 0
Adjuvant radiotherapy N/A
No/missing 458 (31.3%) 56 (4.0%) 525 (18.2%)
Yes 1006 (68.7%) 1339 (96.0%) 2357 (81.8%)
Missing 0 0 0
Adjuvant hormone treatment N/A
No/missing 490 (33.5%) 556 (39.9%) 1059 (36.7%)
Yes 974 (66.5%) 839 (60.1%) 1823 (63.3%)
Missing 0 0 0
EIC indicates extensive intraductal component; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; IQR, interquartile range; PR, progesterone receptor; U/H,
underweight/healthy.
Total column includes data from the whole cohort that is, BCS, mastectomy, and other (23 patients).
yP-value obtained using Pearson x2 test (for categorical variables) or Mann-Whitney test (for continuous variables).
zEIC defined as positive where the total tumor in-situ size is25% the size of the total tumor size (or where the total tumor invasive size is <75% the size of the total tumor size).
FIGURE 2. Local-recurrence interval for
all patients by surgical type. A, Nelson-
Aalen cumulative hazard plot. B, Flexible
parametric survival model time-varying
hazard over time.
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Although UVA demonstrated worse DDFI and OS for mas-
tectomy compared with BCS, this is almost certainly because of
TABLE 2. Local Recurrence Interval Flexible Parametric Survival
Model Multivariable Analysis Results for all Patients (Excluding
Those With Neoadjuvant Chemotherapy)
Covariate HR 95% CI P
Surgical type at 5 years
Mastectomy 1 (Ref. cat.) — —
BCS (unadjusted) 5.33 4.15 to 6.85 <0.001
BCS (adjusted) 5.00 3.57 to 23.69 <0.001
Surgical type at 10 years
Mastectomy 1 (Ref. cat.) — —
BCS (unadjusted) 11.68 9.05 to 15.07 <0.001
BCS (adjusted) 6.06 1.29 to 28.40 0.022
Age at diagnosis, y,
(continuous)
1.02 0.95 to 1.09 0.662
Maximum overall
(invasive þ in situ)
tumor size, (mm)
(continuous)
1.42 0.78 to 2.58 0.253
Focality
Localized 1 (Ref. cat.) — —
Multifocal 1.15 0.58 to 2.30 0.688
N stage
N0 1 (Ref. cat.) — —
N1 1.18 0.71 to 1.96 0.527
Histological grade
1 1 (Ref. cat.) — —
2 1.63 0.38 to 7.02 0.514
3 1.42 0.33 to 6.16 0.636
ER status
Negative 1 (Ref. cat.) — —
Positive 0.64 0.28 to 1.48 0.297
HER2 status
Negative 1 (Ref. cat.) — —
Positive 1.33 0.77 to 2.30 0.306
Adjuvant radiotherapy
No/unknown 1 (Ref. cat.) — —
Yes 0.32 0.16 to 0.64 0.001
Adjuvant hormone therapy
No/unknown 1 (Ref. cat.) — —
Yes 0.64 0.28 to 1.47 0.295
Surgical margins, mm
0 1 (Ref. cat.) — —
0 to <1 0.74 0.26 to 2.14 0.579
1 to 5 0.93 0.40 to 2.18 0.871
>5 0.89 0.36 to 2.22 0.803
CI indicates confidence interval; ER, estrogen receptor; HER2, human epidermal
growth factor receptor 2; HR, hazard ratio.
Unless otherwise stated, HR presented for the multivariable (adjusted) model.
FIGURE 3. Distant disease free interval Kaplan-Meier plot for all
patients by surgical type.
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Similar results were also found in OS. UVA of OS by surgical type
demonstrated that mastectomy patients had a significantly worse OS
compared with BCS (HR, 0.53; 95% CI 0.45–0.62; P < 0.001)
(Fig. 4), and in the MVA the difference was no longer significant
(HR, 0.79; 95% CI 0.61–1.03; P ¼ 0.081) (Supplementary Table 2,
http://links.lww.com/SLA/B64). Excluding ER status, the same fac-
tors also affected the MVA for OS. Moreover, when looking at OS by
local-recurrence event and by surgical margins, the findings matched
those of the DDFI analyses (Supplementary Figure 3A and 3B, http://
links.lww.com/SLA/B64).
DISCUSSION
Previous findings from the POSH study reported on the effects
of ethnicity and obesity, both of which have affected outcome
including DDFI in this young age group,27,28 and family history,
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LRI, DDFI, and OS, and the effect of local recurrence on DDFI and
OS in young women with breast cancer.
A large number of studies use inconsistent definitions of local-
recurrence, often not specifying which events have been included in
the local-recurrence definition.29 This study has therefore clearly
described the definition of local recurrence in the methods with
criteria outlining which events were included/excluded depending on
the time of competing events. This study also incorporated the use of
FPSMs to assess the time-varying effect of surgical type on LRI.
Previous findings from a meta-analysis of RCTs conducted by
the EBCTCG18 presented first recurrence rates (local and distant)
which appeared much higher after BCS in younger women; 36.1% for
women <40 years undergoing BCS with radiotherapy. However, the
number analyzed was relatively small (n ¼ 363) and there was no
breakdown in the meta-analysis of local versus distant recurrences. In
this study, the majority of events were found to be distant and not local
(139 LRI vs 752 DDFI events) which demonstrates the predominant
risk in these young patients is of distant and not local recurrence.FIGURE 4. Overall survival Kaplan-Meier plot for all patients by
surgical type.
 2016 Wolters Kluwer Health, Inc. All rights reserved.
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undergoing mastectomy had significantly larger tumors than BCS,
with a higher proportion of tumors EICþ, and ERþ, PRþ, and/or
HER2þ. Unsurprisingly, tumors of maximum invasive tumor size
>30mm, N1 stage, and grade 3 were significant factors in both DDFI
and OSMVA, the differences between surgical type for DDFI and OS
were no longer significant after correction for these factors. Inter-
estingly, maximum overall (invasive þ in situ) tumor size >30mm
was not a significant factor in either OS or DDFI MVA models,
indicating that whereas overall tumor size influences surgical
decision making, invasive tumor size is the relevant size parameter
predicting DDFI and OS. A sensitivity analysis excluding patients
with a maximum overall tumor size >30mm showed similar results
in a UVA of LRI comparing surgical type.
The results of this study support existing literature in regards
to both OS and DDFI by surgical type, with no evidence of surgical
type affecting survival or distant-disease in this age group. This is
consistent with RCTs comparing mastectomy versus BCS in the
breast cancer population as a whole4–6,11 indicating that surgical
choices for younger women can use accepted criteria without
impacting outcome.
The results of this study also demonstrated similar LRR in the
first 18 months for mastectomy and BCS, but a larger disparity is
seen at 5 and 10 years, with significantly higher LRR for BCS. The
clinical implication is that, at least initially, for local recurrence there
is no disadvantage in treating young women surgically with BCS in
general and no evidence that BCS leads to a disadvantage in DDFI or
OS. It is not yet possible to comment beyond 10 years at this stage for
this cohort. However, other studies suggest LRR continue to rise
beyond 10 years after BCS.19,30
An interesting finding from this study is the effect of margin
on outcomes. Although no effect was seen for LRI, differences were
observed for both OS and DDFI; positive margins were associated
with significantly worse OS and DDFI. This could be because of
reduced power of LRI outcome because of a fewer local-recurrence
events and missing data for margin status, or possibly because of
patients with a positive margin being more likely to present with a
distant relapse, or combination of distant disease and local recur-
rence, which would, as defined here, be considered a distant event, as
these would not be surgically salvageable, isolated local recurrences.
In this analysis, a positive margin was defined according to ASCO
guidance as tumor at the margin.24 Although 24.5% of margin status
information was missing, sensitivity analyses of MVA models using
multiple imputation were carried out and showed very similar results
to the complete-case analyses. The finding that surgical margins are a
factor in the development of distant disease would support the
concept of the importance of surgical quality with attention to
margins, with re-excision where appropriate. Taken together with
the lack of evidence here that oncological surgical type influences
distant-relapse it could be argued that completeness of excision is
more important than the extent of surgery.
In regards to radiotherapy, patients treated with BCS who
were not documented to have adjuvant radiotherapy unsurprisingly
had higher LRR, implying that the datawere correct (rather than data
missing because of patients having radiotherapy elsewhere), and
highlighting the importance of radiotherapy as part of breast con-
servation. Although no effect of radiotherapy boost was shown
for patients undergoing BCS, it must be noted that this is not an
RCT. Interestingly, provision for radiotherapy boost was not shown
to be statistically correlated with margin status; however, the
clinical implication we would draw is that, at least in this study,
provision of a radiotherapy boost appears to be less important than
attention to detail to surgical margins in terms of its effect on LRI
and DDFI.
 2016 Wolters Kluwer Health, Inc. All rights reserved.
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CWR-XRT and a clear association of benefit of CWR-XRT on LRI
has been demonstrated here, despite potential confounding. Given
results of the most recent Oxford overview31 it is likely that
thresholds for CWR-XRT after mastectomy are likely to fall further.
Given that the majority of young patients are likely to receive
radiotherapy, even if surgically treated with mastectomy, there are
likely to be implications for reconstructive decision making.
These findings also support the message that avoiding local
recurrence is important as increased local recurrence is associated
with poorer DDFI and OS.30,32,33 Our data suggest that valid
strategies to reduce local recurrence might include avoidance of a
positive margin after BCS and provision of CWR-XRT after mas-
tectomy where indicated, but do not support mastectomy over BCS
where both options are available.
In this analysis, the frequency of local recurrence is much
lower than that of distant relapse indicating that the main hazard
experienced by these patients, at least within the first 10 years, is of
distant rather than local recurrence. We have not demonstrated an
impact of tumor stage or biological type on local recurrence in this
analysis, possibly because of reduced power because of a lower LRR.
In addition to young age, factors recognized to influence local
recurrence after BCS and mastectomy include axillary nodal status,
margin status, and lack of systemic therapy.34 When considering
molecular subtype a greater proportion of young women appear to
have luminal B tumors2; however, young age remains predictive of
LRR independent of molecular subtype,35 although there is a sug-
gestion that molecular subtype may affect local recurrence.36
Younger patients with breast cancer are also more likely to carry
a germline BRCA-mutation and it is currently unknown whether this
influences LRI or DDFI, although clearly it does increase second new
primary breast tumors; and contralateral new primary events were not
included in this analysis of local recurrence. Once final genotyping in
this cohort has been completed, further analyses will also be per-
formed by BRCA status to see if this has an effect.
Regardless of this, the current Association of Breast Surgery
guidelines state that the target local-recurrence rate after surgery
should be <3% and not >5% at 5 years.37 This study has demon-
strated that LRI in younger patients treated by mastectomy would
fulfill this criterion (HR, 2.63; 95% CI 1.85–3.74), and that the lower
95% LRI limit for younger women undergoing BCS is within this
range (HR, 5.33; 95%CI 4.15–6.85).37 Furthermore, our findings are
consistent with recommendations for breast surgery within recent
consensus guidelines for the management of young women with
breast cancer.38
A limitation of this study is that as this was not an RCT, any
differences/lack of differences in LRI, OS, and/or DDFI were
because of the surgical type alone could be the result of confounding.
However, we have accounted as far as possible for biases and this is a
large prospective cohort representative of cancer treatment in this age
group in the United Kingdom.23 It should be noted this analysis was
performed according to a prespecified plan and LRI was clearly
defined to address the inconsistency of reporting in a number of
previous studies.29
In conclusion, there are no survival advantages for surgical
type after adjusting for known prognostic factors. There is no
difference in LRI between BCS and mastectomy in young women
with breast cancer in the short-term but, beyond 18 months, LRR are
higher after BCS. Local recurrence is associated with increased risk
of distant relapse, and in patients undergoing BCS, a positive surgical
margin increases the likelihood of a distant relapse. For those
undergoing mastectomy, CWR-XRT reduces the likelihood of distant
relapse. Surgical extent therefore appears less important for DDFI
than completeness of excision or, where appropriate, CWR-XRT.
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